Alentis Therapeutics’ 2.5M CHF Swiss Accelerator Project

Alentis Therapeutics is a Swiss biotech company on a mission to treat cancer and reverse fibrosis by targeting claudin-1, a key tight junction protein overexpressed in fibrosis and many cancers. In 2023, Alentis was awarded 2.5M CHF from Innosuisse’s Swiss Accelerator programme for their project, CanEx, to develop ALE.C04, a first-in-class clinical candidate for the…

CÚRAM Partnership: €54M secured from Horizon Europe & SFI

CÚRAM and Catalyze have shared a highly successful partnership since 2018. In this interview we met with Iain Shaw, Operations Director at CÚRAM, to learn more about the development of CÚRAM, and the lasting collaboration with Catalyze along the way. The CÚRAM Centre at the University of Galway. Image: NUIG Summary Established in 2015, CÚRAM,…

PamGene: blood-based biomarkers to predict patient treatment response to immune checkpoint inhibitors

PamGene is a Dutch biomarker services company in Den Bosch that offers scientific research services to academic centres and pharma companies using a proprietary peptide microarray platform, helping cellular kinase signalling analysis in cancer and immune related disorders. They have now developed this platform into an in vitro diagnostic (IVD) test that can predict a…

TETTRIs – a new vision for European taxonomy

Transforming European Taxonomy through Training, Research, and Innovations (TETTRIs), is a Horizon Europe project advancing the field of taxonomy and beyond, with a consortium comprised of 17 institutions from 13 European countries, including research institutions (such as natural history and natural science museums, and botanical gardens) and other biodiversity-related organizations (such as Catalogue of Life,…

Sonohaler: improving treatment of respiratory diseases

Sonohaler is a digital health company headquartered in Copenhagen, Denmark, focused on improving treatment of respiratory diseases with innovative, affordable solutions that are simple to use. In 2022 they were awarded €814K for their project, SMART-HALE, from Eurostars. We spoke with Ash Pradhan, Sonohaler CEO, about their mission, SMART-HALE, and the collaboration with Catalyze. Developing…

3D-Brain Developing a bio-digital twin model of the human brain

The EIC Pathfinder Open project ‘3D-BrAIn’ aims to revolutionize personalized precision medicine for central nervous system (CNS) disorders through development of a bio-digital twin model of the human brain. The project combines breakthrough human brain modelling technology, state-of-the-art 3D multi-electrode array technology, and a novel data analytical approach using tailored biology-inspired automated artificial intelligence (AI)-based…

EIC Transition: PacingCure developing a biological pacemaker

Amsterdam UMC spin-off PacingCure develops platform gene transfer technologies for the heart. In the first cut-off of 2022 their project, TRACTION, was awarded the prestigious Transition grant from the European Innovation Council (EIC). TRACTION aims to establish Proof-of-Concept for BradyTx-01 – a novel gene therapy medicinal product (GTMP) for the curative treatment of life-threatening cardiac…

TargED Biopharmaceuticals: Developing the first targeted clot busting therapy

Established in 2020, TargED Biopharmaceuticals B.V. (NL) is on a mission to accelerate thrombolysis in all forms of thrombosis – the phenomenon of blood clots blocking veins or arteries. Their lead compound, Microlyse, offers targeted and local breakdown of blood clots. Since 2020, Catalyze has collaborated on a number of successful projects with TargED, including…

ERC Starting Grant: Kai Kretzschmar’s €1.77M award to study oral cancer

Approaching the 7-year post-PhD cut-off date for applications to the ERC Starting Grant, Dr. Kai Kretzschmar of the Mildred Scheel Early Career Centre for Cancer Research, a funding initiative of the German Cancer Aid at the University Hospital Würzburg, was awarded almost €1.77 million for his project, OralNiche. The project aims to dissect the impact…

ENPICOM: Addressing major hurdles in the antibody discovery process

ENPICOM’s Innovatiekrediet project, “Antibody development module for immunerepertoire sequencing analysis platform”, secured a €500K contribution from Innovatiekrediet towards €1.2M project costs. In the project, ENPICOM leveraged their cloud software solution, the IGX Platform, to build an Antibody Discovery Module (ADM), in order to address major hurdles in the antibody discovery process. The ADM enables researchers…